Clinical trials: Diabetic Neuralgia
Painful Diabetic Neuropathy, Diabetic Neuropathy, Painful
Phase 3 Gene Therapy for Painful Diabetic Neuropathy
The purpose of this study is to determine the safety and efficacy of bilateral intramuscular injections of VM202 versus placebo in the treatment of painful diabetic peripheral neuropathy.
- Trial name
- NCT02427464
- Testing
- Engensis (VM202)
- Where
- 25 sites in United States
- Volunteers
- 507 people
- Sponsor
- Helixmith Co., Ltd.
Diabetic Peripheral Neuropathic Pain
DS-5565 Phase III Study for Diabetic Peripheral Neuropathic Pain
Investigate the efficacy and safety of DS-5565 in subjects with Diabetic Peripheral Neuropathic Pain (DPNP) in comparison to placebo
- Trial name
- NCT02318706
- Testing
- DS-5565
- Where
- Japan
- Volunteers
- 854 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Diabetic Neuropathic Pain
Genetics of Diabetes Audit and Research in Tayside Scotland (DOLORisk Dundee)
In 1997, the global prevalence of diabetes was estimated to be 125 million and this has risen to around 400 million in 2015. In addition diabetes has a number of complications including heart disease, blindness, kidney failure…
- Trial name
- GoDARTS (NCT02783469)
- Testing
- Identification of genetic causes of diabetic neuropathic pain
- Where
- United Kingdom
- Volunteers
- 1,915 people
- Sponsor
- University of Dundee
Painful Diabetic Neuropathy
Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy (PDN)
The purpose of this study is to evaluate safety and efficacy of EMA401 compared to placebo in patients with painful diabetic neuropathy (PDN).
- Trial name
- EMPADINE (NCT03297294)
- Testing
- EMA401
- Where
- 64 sites in Australia, Austria and 14 more
- Volunteers
- 142 people
- Sponsor
- Novartis Pharmaceuticals
Painful Diabetic Neuropathy
A Trial to Assess the Efficacy and Safety of 400mg/Day Lacosamide in Subjects With Painful Diabetic Neuropathy
The purpose of this trial is to assess whether 400mg/day of lacosamide is effective in reducing pain caused by distal diabetic neuropathy.
- Trial name
- NCT00350103
- Testing
- SPM 929
- Where
- Germany
- Volunteers
- 551 people
- Sponsor
- UCB Pharma
Diabetic Neuropathies
Duloxetine Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain in China
To determine if duloxetine 60mg up to 120mg daily can work in treating pain from Diabetic Neuropathy.
- Trial name
- NCT00408993
- Testing
- Duloxetine Hydrochloride
- Where
- 7 sites in China
- Volunteers
- 215 people
- Sponsor
- Eli Lilly and Company
Diabetic Peripheral Neuropathic Pain
Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Diabetic Peripheral Neuropathic Pain
The purpose of this study is to test the safety and efficacy of study drug LY3526318 for the treatment of diabetic peripheral neuropathic pain (DPNP).
- Trial name
- NCT05177094
- Testing
- LY3526318
- Where
- 37 sites in United States, Puerto Rico
- Volunteers
- 155 people
- Sponsor
- Eli Lilly and Company
Diabetic Neuropathy
An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy
The purpose of this study is to determine the efficacy and safety of Perampanel in patients with painful diabetic neuropathy.
- Trial name
- NCT00505284
- Testing
- E2007 (2 mg), E2007 (4 mg), E2007 (6 mg)
- Where
- United States
- Volunteers
- 352 people
- Sponsor
- Eisai Inc.
Diabetic Peripheral Neuropathic Pain
A Study of Duloxetine (LY248686) in Participants With Diabetic Peripheral Neuropathic Pain (DPNP)
The main purpose of this study is to evaluate the effectiveness and safety of the study drug known as duloxetine in participants with diabetic peripheral neuropathic pain.
- Trial name
- NCT02417935
- Testing
- Duloxetine, Pregabalin
- Volunteers
- 304 people
- Sponsor
- Eli Lilly and Company
Peripheral Neuropathy, Neuropathic Pain
Safety and Efficacy Study of ADL5859 in Participants With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
The purpose of this study is to evaluate the effectiveness of ADL5859 in relieving the pain associated with diabetic peripheral neuropathy (DPN) compared with placebo and duloxetine (a marketed drug approved for the treatment of…
- Trial name
- NCT00603265
- Testing
- ADL5859, Duloxetine
- Where
- 27 sites in United States
- Volunteers
- 226 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Painful Diabetic Neuropathy
Efficacy and Safety of MEDI7352 in Participants With Painful Diabetic Neuropathy
This is a study investigating the effect of MEDI7352 on chronic pain in participants with painful diabetic neuropathy. The study incudes a screening period of up to 45 days and a 12-week treatment period during which MEDI7352 or…
- Trial name
- NCT03755934
- Testing
- MEDI7352
- Where
- 31 sites in Denmark, Hungary and 3 more
- Volunteers
- 112 people
- Sponsor
- AstraZeneca
Painful Diabetic Neuropathy
Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Painful Diabetic Neuropathy
The primary objective of the study is to assess the efficacy of eslicarbazepine acetate (ESL) as therapy for patients with painful diabetic neuropathy.
- Trial name
- NCT00980746
- Testing
- Eslicarbazepine acetate
- Volunteers
- 557 people
- Sponsor
- Bial - Portela C S.A.
Diabetic Peripheral Neuropathic Pain
A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05).
This study is being done to test the safety and efficacy of the study drug LY3857210 for the treatment of diabetic peripheral neuropathic pain.
- Trial name
- NCT05620576
- Testing
- LY3857210
- Where
- 30 sites in United States, Puerto Rico
- Volunteers
- 131 people
- Sponsor
- Eli Lilly and Company
Diabetic Neuropathies
Maintenance of Effect of Duloxetine in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)
To determine if duloxetine 60 mg once daily can work up to 6 months in treating pain from Diabetic Neuropathy.
- Trial name
- NCT00322621
- Testing
- Duloxetine
- Where
- 19 sites in Brazil, France and 2 more
- Volunteers
- 216 people
- Sponsor
- Eli Lilly and Company
Diabetic Neuropathy, Painful; Diabetic Neuropathies
Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability
This is a 2-part study. In Part 1 of the study, subjects will undergo a pain reporting training program in which a painful stimulus will be applied to the subject's hand, and the subjects will be asked to report how painful the…
- Trial name
- NCT01928381
- Testing
- AZD5213 + pregabalin, pregabalin capsules
- Where
- 9 sites in United States
- Volunteers
- 150 people
- Sponsor
- AstraZeneca
Diabetic Peripheral Neuropathic Pain (DPN), Postherpetic Neuralgia (PHN)
Pregabalin Treatment Of Peripheral Neuropathic Pain Associated With Diabetic Peripheral NeP (DPN), Postherpetic Neuralgia (PHN), HIV-related NeP (HIV), and Chemotherapy Induced NeP
Management of neuropathic pain associated with diabetic peripheral neuropathy, post-herpetic neuralgia, human immunodeficiency virus-related peripheral neuropathy, and chemotherapy induced peripheral neuropathy.
- Conditions
- Diabetic Peripheral Neuropathic Pain (DPN), Postherpetic Neuralgia (PHN), HIV-related Neuropathic Pain (HIV), Chemotherapy Induced Neuropathic Pain
- Trial name
- NCT00407511
- Testing
- Pregabalin
- Where
- 11 sites in Colombia, Ecuador and 3 more
- Volunteers
- 121 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Diabetic Neuropathies
A Long-term Study for the Treatment of Painful Diabetic Neuropathy
The purpose of the study is to investigate safety and efficacy of duloxetine for patients with painful diabetic neuropathy at long-term use.
- Trial name
- NCT00641719
- Testing
- Duloxetine hydrochloride
- Where
- 25 sites in Japan
- Volunteers
- 258 people
- Sponsor
- Eli Lilly and Company
Diabetic Neuropathies, Pain
Study Evaluating Desvenlafaxine Succinate Sustained-release (DVS SR) in Adult Outpatients With Pain Associated With Diabetic Peripheral Neuropathy
The purpose of this study is to evaluate the safety and efficacy of DVS SR in the treatment of neuropathic pain associated with diabetic peripheral neuropathy.
- Trial name
- NCT00283842
- Testing
- DVS SR
- Where
- 51 sites in United States
- Volunteers
- 408 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Painful Diabetic Neuropathy
Quantitative Assessment of Painful Diabetic Peripheral Neuropathy After High Frequency Spinal Cord Stimulation
Will participants with painful lower extremity diabetic peripheral neuropathy (DPN) that are treated with high frequency spinal cord stimulation (HF10 SCS) have improvements in lower extremity peripheral nerve function?
- Trial name
- NCT03769675
- Testing
- High Frequency Spinal Cord Stimulator
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Mayo Clinic
Diabetic Peripheral Neuropathic Pain, Diabetic Peripheral Neuropathy
Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy and Safety of ETX 018810 in Subjects with Diabetic Peripheral Neuropathic Pain.
- Trial name
- NCT04688671
- Testing
- ETX-018810
- Where
- 22 sites in United States
- Volunteers
- 167 people
- Sponsor
- Eliem Therapeutics (UK) Ltd.